系统性红斑狼疮中LINE-1编码p40自身抗体的高患病率及疾病相关性
本研究用纯化p40蛋白通过免疫印迹和ELISA定量172例SLE患者及疾病对照和年龄匹配健康对照血清中的IgG自身抗体。SLE患者抗p40抗体水平高于健康对照(P=0.01),且与疾病活动度、干扰素评分、补体C3下降、抗DNA抗体、抗C1q抗体及肾炎病史相关。结论:抗LINE-1 p40自身抗体标识一组病情严重且活动的SLE患者。
要点
- SLE患者抗LINE-1 p40抗体水平显著高于健康对照(P=0.01)。
- 抗p40抗体与SLE疾病活动指数(P=0.0002)及I型干扰素评分(P=0.006)相关。
- 抗p40抗体与补体C3下降、抗DNA抗体、抗C1q抗体及肾炎病史相关。
核心结论
- 抗LINE-1 p40自身抗体标识一组病情严重且活动的SLE患者。
- 这些抗体可能代表针对LINE-1 p40的早期免疫反应,本身不意味着临床显著的自身免疫,但可能是SLE发病中早期且仍可逆的一步。
研究设计与样本
- 用高度纯化的p40蛋白通过免疫印迹和酶联免疫吸附试验(ELISA)定量172例SLE患者及疾病对照和年龄匹配健康对照血清中的IgG自身抗体。
- 用患者血清对含p40相关蛋白的制备物进行免疫印迹分析。
主要发现
- 多数患者和许多健康对照中可检测到与p40反应的抗体,SLE患者水平高于健康对照(P=0.01),但系统性硬化症患者与健康对照相比未显示升高。
- 抗p40反应在疾病 flare 期患者中高于缓解期患者(P=0.03)。
- 抗p40反应与SLE疾病活动指数评分(P=0.0002)、I型干扰素评分(P=0.006)、补体C3水平下降(P=0.0001)、抗DNA抗体存在(P<0.0001)、抗C1q抗体存在(P=0.004)以及当前或既往肾炎病史(分别P=0.02和P=0.003)相关。
- 抗p40反应与年龄呈负相关(r=-0.49,P<0.0001)。
- SLE患者血清也与p40相关蛋白发生反应。
关键数值与推荐
- 抗p40抗体水平在SLE患者与健康对照间差异P=0.01。
- 抗p40反应与SLE疾病活动指数评分相关P=0.0002,与I型干扰素评分相关P=0.006,与补体C3下降相关P=0.0001,与抗DNA抗体相关P<0.0001,与抗C1q抗体相关P=0.004,与当前肾炎病史相关P=0.02,与既往肾炎病史相关P=0.003。
- flare期与缓解期抗p40反应差异P=0.03;抗p40反应与年龄负相关r=-0.49,P<0.0001。
临床怎么用
- 抗LINE-1 p40自身抗体可能有助于识别病情严重且活动的SLE患者人群。
- 检测抗p40抗体可结合疾病活动度、I型干扰素评分、补体C3、抗DNA抗体、抗C1q抗体及肾炎病史综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Long interspersed nuclear element 1 (LINE-1) encodes 2 proteins, the RNA binding protein p40 and endonuclease and reverse transcriptase (open-reading frame 2p [ORF2p]), which are both required for LINE-1 to retrotranspose. In cells expressing LINE-1, these proteins assemble with LINE-1 RNA and additional RNA binding proteins, some of which are well-known autoantigens in patients with systemic lupus erythematosus (SLE). This study was undertaken to investigate whether SLE patients also produce autoantibodies against LINE-1 p40. METHODS: Highly purified p40 protein was used to quantitate IgG autoantibodies in serum from 172 SLE patients and from disease controls and age-matched healthy subjects by immunoblotting and enzyme-linked immunosorbent assay (ELISA). Preparations of p40 that also contained associated proteins were analyzed by immunoblotting with patient sera. RESULTS: Antibodies reactive with p40 were detected in the majority of patients and many healthy controls. Their levels were higher in patients with SLE, but not those with systemic sclerosis, compared to healthy subjects (P = 0.01). Anti-p40 reactivity was higher in patients during a flare than in patients with disease in remission (P = 0.03); correlated with the SLE Disease Activity Index score (P = 0.0002), type I interferon score (P = 0.006), decrease in complement C3 level (P = 0.0001), the presence of anti-DNA antibodies (P < 0.0001) and anti-C1q antibodies (P = 0.004), and current or past history of nephritis (P = 0.02 and P = 0.003, respectively); and correlated inversely with age (r = -0.49, P < 0.0001). SLE patient sera also reacted with p40-associated proteins. CONCLUSION: Autoantibodies reacting with LINE-1 p40 characterize a population of SLE patients with severe and active disease. These autoantibodies may represent an early immune response against LINE-1 p40 that does not yet by itself imply clinically significant autoimmunity, but may represent an early, and still reversible, step toward SLE pathogenesis.
引用
- Carter V, LaCava J, Taylor MS, et al. High Prevalence and Disease Correlation of Autoantibodies Against p40 Encoded by Long Interspersed Nuclear Elements in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020. PMID: 31342656. doi:10.1002/art.41054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。